vs
Orange County Bancorp, Inc.（OBT）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Orange County Bancorp, Inc.的季度营收约是REGENXBIO Inc.的1.1倍（$33.0M vs $30.3M），Orange County Bancorp, Inc.净利率更高（37.6% vs -221.3%，领先259.0%），REGENXBIO Inc.同比增速更快（43.0% vs 20.6%），Orange County Bancorp, Inc.自由现金流更多（$41.3M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 14.3%）
奥兰治县银行控股公司注册于美国特拉华州，主要在纽约州开展业务，为个人消费者、小微企业及中型企业客户提供全面的零售与商业银行服务，涵盖存款账户、各类贷款、财富管理解决方案等金融产品。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
OBT vs RGNX — 直观对比
营收规模更大
OBT
是对方的1.1倍
$30.3M
营收增速更快
RGNX
高出22.4%
20.6%
净利率更高
OBT
高出259.0%
-221.3%
自由现金流更多
OBT
多$94.1M
$-52.8M
两年增速更快
RGNX
近两年复合增速
14.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.0M | $30.3M |
| 净利润 | $12.4M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 41.4% | -190.0% |
| 净利率 | 37.6% | -221.3% |
| 营收同比 | 20.6% | 43.0% |
| 净利润同比 | 73.5% | -31.2% |
| 每股收益（稀释后） | $0.94 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OBTRGNX
| Q4 25 | $33.0M | $30.3M | ||
| Q3 25 | $33.7M | $29.7M | ||
| Q2 25 | $32.5M | $21.4M | ||
| Q1 25 | $28.0M | $89.0M | ||
| Q4 24 | $27.4M | $21.2M | ||
| Q3 24 | $27.1M | $24.2M | ||
| Q2 24 | $27.9M | $22.3M | ||
| Q1 24 | $25.3M | $15.6M |
净利润OBTRGNX
| Q4 25 | $12.4M | $-67.1M | ||
| Q3 25 | $10.0M | $-61.9M | ||
| Q2 25 | $10.5M | $-70.9M | ||
| Q1 25 | $8.7M | $6.1M | ||
| Q4 24 | $7.2M | $-51.2M | ||
| Q3 24 | $3.2M | $-59.6M | ||
| Q2 24 | $8.2M | $-53.0M | ||
| Q1 24 | $9.3M | $-63.3M |
毛利率OBTRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率OBTRGNX
| Q4 25 | 41.4% | -190.0% | ||
| Q3 25 | 38.6% | -176.3% | ||
| Q2 25 | 41.9% | -296.3% | ||
| Q1 25 | 40.3% | 13.6% | ||
| Q4 24 | 32.8% | -242.1% | ||
| Q3 24 | 14.8% | -256.6% | ||
| Q2 24 | 36.6% | -251.3% | ||
| Q1 24 | 45.9% | -408.8% |
净利率OBTRGNX
| Q4 25 | 37.6% | -221.3% | ||
| Q3 25 | 29.7% | -208.3% | ||
| Q2 25 | 32.2% | -331.8% | ||
| Q1 25 | 31.1% | 6.8% | ||
| Q4 24 | 26.2% | -241.3% | ||
| Q3 24 | 11.8% | -246.3% | ||
| Q2 24 | 29.4% | -237.7% | ||
| Q1 24 | 36.7% | -405.4% |
每股收益（稀释后）OBTRGNX
| Q4 25 | $0.94 | $-1.30 | ||
| Q3 25 | $0.75 | $-1.20 | ||
| Q2 25 | $0.87 | $-1.38 | ||
| Q1 25 | $0.77 | $0.12 | ||
| Q4 24 | $0.64 | $-0.99 | ||
| Q3 24 | $0.28 | $-1.17 | ||
| Q2 24 | $0.73 | $-1.05 | ||
| Q1 24 | $0.82 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $284.4M | $102.7M |
| 总资产 | $2.7B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OBTRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益OBTRGNX
| Q4 25 | $284.4M | $102.7M | ||
| Q3 25 | $270.1M | $161.5M | ||
| Q2 25 | $252.6M | $213.7M | ||
| Q1 25 | $201.3M | $274.2M | ||
| Q4 24 | $185.5M | $259.7M | ||
| Q3 24 | $193.1M | $301.4M | ||
| Q2 24 | $177.5M | $348.3M | ||
| Q1 24 | $168.7M | $390.7M |
总资产OBTRGNX
| Q4 25 | $2.7B | $453.0M | ||
| Q3 25 | $2.6B | $525.2M | ||
| Q2 25 | $2.6B | $581.0M | ||
| Q1 25 | $2.6B | $490.9M | ||
| Q4 24 | $2.5B | $466.0M | ||
| Q3 24 | $2.5B | $519.1M | ||
| Q2 24 | $2.5B | $569.4M | ||
| Q1 24 | $2.5B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $43.8M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $41.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | 125.1% | -174.0% |
| 资本支出强度资本支出/营收 | 7.6% | 1.7% |
| 现金转化率经营现金流/净利润 | 3.53× | — |
| 过去12个月自由现金流最近4个季度 | $69.6M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流OBTRGNX
| Q4 25 | $43.8M | $-52.3M | ||
| Q3 25 | $30.2M | $-56.0M | ||
| Q2 25 | $-5.0M | $-49.3M | ||
| Q1 25 | $4.8M | $33.6M | ||
| Q4 24 | $34.6M | $-31.6M | ||
| Q3 24 | $10.2M | $-40.5M | ||
| Q2 24 | $9.3M | $-45.5M | ||
| Q1 24 | $2.3M | $-55.5M |
自由现金流OBTRGNX
| Q4 25 | $41.3M | $-52.8M | ||
| Q3 25 | $29.6M | $-56.5M | ||
| Q2 25 | $-5.7M | $-49.7M | ||
| Q1 25 | $4.3M | $32.6M | ||
| Q4 24 | $32.9M | $-32.7M | ||
| Q3 24 | $10.0M | $-40.9M | ||
| Q2 24 | $9.2M | $-46.0M | ||
| Q1 24 | $2.0M | $-56.0M |
自由现金流率OBTRGNX
| Q4 25 | 125.1% | -174.0% | ||
| Q3 25 | 87.8% | -189.9% | ||
| Q2 25 | -17.5% | -232.8% | ||
| Q1 25 | 15.5% | 36.6% | ||
| Q4 24 | 120.0% | -154.2% | ||
| Q3 24 | 36.7% | -168.9% | ||
| Q2 24 | 32.8% | -206.2% | ||
| Q1 24 | 7.9% | -358.5% |
资本支出强度OBTRGNX
| Q4 25 | 7.6% | 1.7% | ||
| Q3 25 | 1.8% | 1.7% | ||
| Q2 25 | 2.3% | 1.8% | ||
| Q1 25 | 1.8% | 1.2% | ||
| Q4 24 | 6.3% | 5.1% | ||
| Q3 24 | 1.1% | 1.3% | ||
| Q2 24 | 0.4% | 2.1% | ||
| Q1 24 | 1.0% | 3.6% |
现金转化率OBTRGNX
| Q4 25 | 3.53× | — | ||
| Q3 25 | 3.01× | — | ||
| Q2 25 | -0.47× | — | ||
| Q1 25 | 0.56× | 5.53× | ||
| Q4 24 | 4.83× | — | ||
| Q3 24 | 3.19× | — | ||
| Q2 24 | 1.13× | — | ||
| Q1 24 | 0.24× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OBT
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
